262 related articles for article (PubMed ID: 2524404)
1. Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception.
Knuth UA; Yeung CH; Nieschlag E
Fertil Steril; 1989 Jun; 51(6):1011-8. PubMed ID: 2524404
[TBL] [Abstract][Full Text] [Related]
2. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
Soufir JC; Jouannet P; Marson J; Soumah A
Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
[TBL] [Abstract][Full Text] [Related]
3. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
4. Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men.
Pangkahila W
Int J Androl; 1991 Aug; 14(4):248-56. PubMed ID: 1831798
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
Guerin JF; Rollet J
Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
[TBL] [Abstract][Full Text] [Related]
6. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
7. Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters.
Barfield A; Melo J; Coutinho E; Alvarez-Sanchez F; Faundes A; Brache V; Leon P; Frick J; Bartsch G; Weiske WH; Brenner P; Mishell D; Bernstein G; Ortiz A
Contraception; 1979 Aug; 20(2):121-7. PubMed ID: 487815
[TBL] [Abstract][Full Text] [Related]
8. The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme.
Bain J; Rachlis V; Robert E; Khait Z
Contraception; 1980 Apr; 21(4):365-79. PubMed ID: 6771093
[TBL] [Abstract][Full Text] [Related]
9. Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptive.
Brenner PF; Mishell DR; Bernstein GS; Ortiz A
Contraception; 1977 Jun; 15(6):679-91. PubMed ID: 891194
[TBL] [Abstract][Full Text] [Related]
10. Spermatogenesis in men treated with injections of medroxyprogesterone acetate combined with testosterone enanthate.
Frick J; Danner C; Kunit G; Joos H; Köhle R
Int J Androl; 1982 Jun; 5(3):246-52. PubMed ID: 7118265
[TBL] [Abstract][Full Text] [Related]
11. Use of low-dosage oral cyproterone acetate as a male contraceptive.
Wang C; Yeung KK
Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
[TBL] [Abstract][Full Text] [Related]
12. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men.
Foegh M; Nicol K; Petersen IB; Schou G
Contraception; 1980 Jun; 21(6):631-40. PubMed ID: 6775869
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunoassays of ethinyl-norgestrienone (R-2323) and medroxyprogesterone acetate (MPA) and their clinical applicability.
Frick J; Bartsch G; Jakse G
Urol Res; 1977; 5(2):55-9. PubMed ID: 69351
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in indonesian men. World Health Organization. Task Force on Methods for the Regulation of Male Fertility.
Fertil Steril; 1993 Dec; 60(6):1062-8. PubMed ID: 8243687
[TBL] [Abstract][Full Text] [Related]
16. The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. I. Uniform dosage levels.
Frick J; Bartsch G; Weiske WH
Contraception; 1977 Jun; 15(6):649-68. PubMed ID: 891192
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial of 19-nortestosterone-hexoxyphenylpropionate (Anadur) for male fertility regulation.
Knuth UA; Behre H; Belkien L; Bents H; Nieschlag E
Fertil Steril; 1985 Dec; 44(6):814-21. PubMed ID: 3935486
[TBL] [Abstract][Full Text] [Related]
19. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
[TBL] [Abstract][Full Text] [Related]
20. Return of ovulation following a single injection of depo-medroxyprogesterone acetate: a pharmacokinetic and pharmacodynamic study.
Lan PT; Aedo AR; Landgren BM; Johannisson E; Diczfalusy E
Contraception; 1984 Jan; 29(1):1-18. PubMed ID: 6234145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
